search for


Proteomic Analysis of Human Adipose Derived Stem Cells during Small Molecule Chemical Stimulated Pre-neuronal Differentiation
International Journal of Stem Cells 2017;10:193-217
Published online November 30, 2017;  
© 2017 Korean Society for Stem Cell Research.

Jerran Santos1,2, Bruce K Milthorpe1, Benjamin R Herbert3, and Matthew P Padula2

1Advanced Tissue Regeneration & Drug Delivery Group, School of Life Sciences, University of Technology Sydney, NSW, Australia, 2Proteomics Core Facility, School of Life Sciences, University of Technology Sydney, NSW, Australia, 3Northern Clinical School, Sydney Medical School, University of Sydney, NSW, Australia
Correspondence to: Jerran Santos, Faculty of Science, University of Technology Sydney, Office 04.07.430, Building 4 Cnr Thomas and Harris Streets, Ultimo 2007, NSW, Australia, Tel: +61-2-9514-8374, Fax: +61-2-9514-8206, E-mail:
; Accepted July 4, 2017.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Adipose derived stem cells (ADSCs) are acquired from abdominal liposuction yielding a thousand fold more stem cells per millilitre than those from bone marrow. A large research void exists as to whether ADSCs are capable of transdermal differentiation toward neuronal phenotypes. Previous studies have investigated the use of chemical cocktails with varying inconclusive results.


Human ADSCs were treated with a chemical stimulant, beta-mercaptoethanol, to direct them toward a neuronal-like lineage within 24 hours. Quantitative proteomics using iTRAQ was then performed to ascertain protein abundance differences between ADSCs, beta-mercaptoethanol treated ADSCs and a glioblastoma cell line.


The soluble proteome of ADSCs differentiated for 12 hours and 24 hours was significantly different from basal ADSCs and control cells, expressing a number of remodeling, neuroprotective and neuroproliferative proteins. However toward the later time point presented stress and shock related proteins were observed to be up regulated with a large down regulation of structural proteins. Cytokine profiles support a large cellular remodeling shift as well indicating cellular distress.


The earlier time point indicates an initiation of differentiation. At the latter time point there is a vast loss of cell population during treatment. At 24 hours drastically decreased cytokine profiles and overexpression of stress proteins reveal that exposure to beta-mercaptoethanol beyond 24 hours may not be suitable for clinical application as our results indicate that the cells are in trauma whilst producing neuronal-like morphologies. The shorter treatment time is promising, indicating a reducing agent has fast acting potential to initiate neuronal differentiation of ADSCs.

Keywords : Adult Stem Cells, Adipose, Neuronal, Proteomics, Cytokines

Regenerative and translational medicine is a rapidly expanding area made possible by the availability of an abundant source of adipose derived stem cells (ADSCs) from lipoaspirates, less abundant bone marrow derived stem cells (BMSCs) and induced pluripotent stem cells (iPSCs). The need for regenerative therapies in osteogenesis and chondrogenesis has increased interest in transdifferentiation of these cells for autologous transplants and therapy development (1). Not surprisingly, neuronal regeneration and repair therapies are of great interest because of its potential to reverse injuries that have severe effects on quality of life (2, 3).

The generation of differentiated neuronal cells from progenitor stem cells has been attempted by a number of researchers over the last decade (46). Several have reported the successful passage of ADSCs and BMSCs, in vitro and in vivo, in the presence of simple chemicals and/or growth factors, such as beta-mercaptoethanol (BME) (7, 8), retinoic acid (RA) (9), dimethylsulfoxide (DMSO) and Butylated hydroxianisole (BHA), to rapidly differentiate morphologically toward a neuronal linage. The resultant cell populations have been shown to express morphological and protein surface marker identities consistent with that seen in primary derived neuronal tissue and cultured neuronal cell lines.

BME is a reducing agent and has been shown to be toxic to certain cell types when presented in concentrations higher than the micromolar range (10). The potential for BME to be used as an inducing agent for neuronal differentiation has been studied in a limited capacity (4, 5) and shown to rapidly cause differentiation into cells presenting neuronal-like morphologies within 24 hours of induction (4, 5, 7, 8). Consistent with these morphological changes, BME induced MSCs have been noted to express neuronal specific markers such as Neuron specific enolase (NSE), β-Tubulin 3 (βT3), Glial Fibral Acidic Protein (GFAP), S-100 and Neudesin (NENF) (4, 5, 7, 8).

However, determining the functionality of the produced cells has proved to be much more difficult. The function of BME transdifferentiated cells or the ability of the produced cells to conduct an action potential would prove the cells produced are terminally differentiated neurons. Barnabé et al. (7) conducted patch clamping to detect the Na+ and K+ currents to determine electrophysiological potential, revealing that the produced cells did not show evidence of Na+ or K+ currents nor the ability to fire action potentials.

The characterisation of differentiation by determining the presence of a small number of markers using antibodies in Western blot or immunofluorescence can result in a false impression of the extent of differentiation. By examining the proteome profiles, an unbiased comparative and quantitative measurement of the extent of biological change through the differentiation process can be performed. Thus the aim of this study is the examination of these cells at the proteome level to investigate the changes in protein abundance of differentiating ADSCs in the presence of beta-mercaptoethanol.

Experimental Procedures

Cell culture

This research was approved by the Macquarie University human research ethics committee (Ref #: 5201100385). The procedure described below is adapted from Bunnell et al. (11). Adult ADSCs were derived from abdominal lipoaspirates and subsequent steps were conducted under sterile conditions in a class II laminar flow hood (Clyde-Apac BH2000 series). Lipoaspirates were rinsed twice in Dulbecco’s Modified Eagle’s Medium (D-MEM, Gibco), connective tissue digested with collagenase type 1 (Gibco) for 45 minutes at 37°C before centrifugation at 1600×g for 10 minutes at 4°C to separate adipocytes from the stromal vascular fraction (SVF). The pellet was resuspended in 3 ml of D-MEM and layered on top of 3 ml of Ficoll Paque PLUS (Sigma-Aldrich) to remove red blood cells from the SVF. The resulting purified stromal vascular fraction (SVF) was aliquoted into a T25 culture flask (Nunc) in Delbucco’s modified eagle medium (D-MEM) Glutmax/F12 (Gibco) with 10% Fetal bovine serum (FBS) (Invitrogen) and 1% antibiotics/antimycotics (ABAM) (Invitrogen) and incubated at 37°C at 5% CO2 for 48 hours until ADSCs adhered to the culture flask. Non-adherent cells were eliminated by replacing the media. All isolations were confirmed CD45 negative and CD90 positive (data not shown). ADSCs were passaged 3~5 times by detaching cells with TrypLE Express (Gibco) and before being utilised in differentiation experiments.

Chemical induction for differentiation

Subconfluent ADSCs were washed twice in pre-warmed sterile D-MEM/F12 (Invitrogen). The cells were then cultured for a further 24 hours in a serum-free pre-induction medium consisting of D-MEM/F12 (Invitrogen), Antibiotics-Antimycotics (ABAM, Invitrogen) and 1 mM β-mercaptoethanol (Sigma). The media was then replaced after 24 hrs with the neural inducing media consisting of D-MEM/F12 (Invitrogen), ABAM (Invitrogen) and 10 mM β-mercaptoethanol (Sigma) as per Woodbury et al. (4).

Glioblastoma cell culture

GBCs line (NCH612 Cell Line Service, Germany) were cultured D-MEM/F12 (Invitrogen), ABAM (Invitrogen). The cells were grown to 90% confluence prior to passaging or harvesting for proteomics.


Cell counts

In vitro cell counts were carried out utilising a novel procedure to determine the approximate colony forming units per square millimetre of cells adherent to the culture flask which were induced for differentiation and subsequently utilised for proteomics. A grid of squares 2.5 ×2.5 mm was printed on a transparent laminate and cut to fit outer bottom side of a T175 culture flask (BD Falcon). Ten squares were chosen and cells counted at 100× on an Olympus CK40 inverted microscope and the cell counts from the ten squares were averaged for each flask to find a mean total cfu per square. For the flask total cell population, the averaged cell number was multiplied by 28000 (16squares*10*175 cm) to find the total cell population in the T175 culture flask. To find cfu/mm2 the average cell number from the ten squares were divided by 2.5 mm. At the final time point cells were removed from the culture flask and an aliquot was stained with trypan blue to determine live/dead ratio using a Neubauer chamber. The total cell number data was also utilised in the Bioplex analysis (described below) to determine the amount of cytokines secreted per cell. This was calculated by multiplying the concentration by the total volume of the flask and dividing by the total cell number at the respective time point. Stained cells were visualised on an Olympus IX51 inverted microscope and images captured with the attached Olympus DP70 camera.

Protein Extraction

Culture media was decanted and the cells washed 2~3 times with sterile 1× Phosphate buffered saline (PBS). Cells were harvested by treating cells with 3 ml TrypLE Express (12604 Gibco) for 10~15 minutes at 37°C. Detached cells were rinsed and collected in 10 ml of sterile 1× PBS in a 15 ml falcon tube. Cells were centrifuged at 1000 rcf for 10 minutes to pellet. Supernatant was decanted and the cell pellet was resuspended in 100 μl of 1% SDS and transferred to 0.65 ml eppendorf tube and boiled for 10 minutes to lyse cell pellets. Lysates were centrifuged at 16000 rcf for 10 minutes to pellet debris. Supernatant was then buffer exchanged into 0.1% SDS with SCC Micro-Biospin columns (BioRad).

1D Electrophoresis

Samples were diluted 1:1 with SDS loading buffer (Invitrogen), heated at 95°C for 10 minutes then centrifuged. Samples were then loaded into 4~12% Bis-Tris Criterion gel (BioRad) in XT-MES (BioRad) running buffer then electrophoresed according to the standard product protocol of 160 V for 50 minutes (BioRad). Upon completion of electrophoresis, gels were either used in western blots or fixed and stained with Flamingo fluorescent protein stain (Biorad). Gels were imaged using a PharosFX Plus (Biorad) imager and Quantity One software (BioRad). The gel was then was over stained with Coomassie Blue G stain for visual comparison.

Western Blot

The Western blot method was adapted from Jobbins et al. (12). The membrane was then placed in a solution containing the one of the following primary monoclonal antibodies: mouse anti-human NeuN/Fox3 (M377100 Biosensis 1:5000), mouse anti-human NF200 (M988100 Biosensis 1:500), rabbit anti-human βT3 (ab18207 Abcam 1:1000) or rabbit anti-human GFAP (ab7260 Abcam 1:50000) diluted in PBS respectively and incubated overnight at 4°C on a gentle rocker. Subsequently washed 3 times with PBS and probed with a secondary antibody either and anti-mouse IgG (A4416 Sigma) or anti-rabbit IgG (A4312 Sigma) dependent on the primary probe. Secondary antibodies were peroxidase or alkaline phosphatase conjugated for development with 3, 3-Diaminobenzidine (DAB) (Sigma) or 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium chloride (BCIP/NBT) (Sigma) respectively.


ADSCs and differentiation conditioned media in 500 μl aliquots were collected at time 0min as a control and at 30 min, 1 hr, 3 hrs, 5 hrs, 20 hrs and 24 hrs subsequent to adding the differentiation media and then stored at −80 degC till assay. Concentrations of IL-1ra, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, Eotaxin, FGF basic, G-CSF, GM-CSF, IFN-γ, MCP-1, MIP-1a, MIP-1b, PDGF-bb, RANTES, TNF-α and vEGF were simultaneously evaluated using a commercially available multiplex bead-based sandwich immunoassay kits (Bioplex human 27-plex, M50-0KCAF0Y BioRad Laboratories). Assays were performed according to the manufacturer’s instructions.


After cell lysis and protein extraction the total of 4 samples for iTRAQ labelling (1~ ADSCs, 2~ 12 hr BME Differentiation hADSC, 3~24 hr BME Differentiation hADSC and 4~ Glioblastoma control [GBCs]) were buffer exchanged in 0.1% SDS using a Tris free Micro Bio-Spin Chromatography Columns (BioRad) and made up to a final concentration of 60 μg/100 μl each. iTRAQ labelling was performed as per manufacturer’s instructions. Following labelling, samples were combined and fractionated by strong-cation exchange (SCX) chromatography with Polysulfoethyl A column. The SCX fractions were injected with an Eksigent Ultra nanoLC system (Eksigent) onto a ProteCol C18 column (SGE) and peptides eluted using a linear gradient at 600 nl/min over 100 minutes. The eluent was subject to positive ion nanoelectrospray analysis in an information dependant acquisition mode (IDA) with a TripleTOF 5600 (AB Sciex). In IDA mode, a TOFMS survey scan was acquired (m/z 400~1,500, 0.25 second), with the ten most intense multiply charged ions (counts >150) in the survey scan sequentially subjected to MS/MS analysis. MS/MS spectra were accumulated for 200 milliseconds in the mass range m/z 100~1500 with the total cycle time 2.3 seconds. MS/MS data were submitted to ProteinPilot V4.0 (AB Sciex) for data processing using Homo sapiens species. Bias correction was selected. The detected protein threshold (unused ProtScore) was set as larger than 1.3 (better than 95% confidence). FDR (False discovery rate) Analysis was selected. A minimum of five peptide cut-off stringency was used to identify proteins. Volcano plots, Gene ontology and Bioplex heat maps were generated using DanteR software (13).



Human ADSCs (hADSCs) were cultured producing a morphologically homogenous culture with cells exhibiting the spindle-fibroblastic form consistent with current literature. The cells were maintained at subconfluency prior to addition of differentiation media containing BME as per Woodbury et al. (4). Fig. 1A~D shows the rate of cellular remodelling over a 24 hour period after the addition of the differentiation media. Basal ADSCs (Fig. 1A) generally grow in a flat, large fibroblastic configuration. Within 3 hours (Fig. 1B) of neuronal induction the morphological changes became evident with a number of cells showing signs of cytoplasmic retraction toward the nucleus of the cell. The now elongated membrane produced a firm and contracted bipolar or multi-polar configuration. At the 12 hour time point (Fig. 1C) the cells morphological changes are ubiquitous across the cultured population with a majority of the cells presenting the retracted cytoplasm and multi-polar shape with evidence of extensions and processes reaching between cells. The cell bodies appear condensed and light refractive compared to the basal hADSCs. At the 24 hour time point prior to harvesting, the cells have a unique morphology compared to the basal state hADSCs with the majority of adherent cells producing polar extensions and processes reaching between cells with some evidence of detachment. In summary these cells morphologically appear to resemble neuronal cells.

iTRAQ proteome comparisons of hADSCs, 12 hour, 24 hour differentiated and GBCs control

The digested proteins from each cell line were labelled with the iTRAQ isobaric tags as follows: hADSCs, 12 hour differentiated hADSCs, 24 hour differentiated hADSCs and GBCs labelled with 114, 115, 116 and 117 isobaric tags respectively. The protein fold changes between samples were done comparatively and are relative to a base denominator, the basal hADSCs -114, and all comparisons were made relative to this, i.e. 115 vs 114, 116 vs 114 and 117 vs 114. This was done to elucidate the relative protein fold changes across the captured and labelled proteome of the differentiating cells, determining the up or down regulation of protein species over time during differentiation.

Table 1 summarises the iTRAQ results of basal hADSCs, hADSCs differentiated for 12 hours, hADSCs differentiated for 24 hours and a control GBCs cell line. The summary table shows the upper 99%, 95% and 66% cut off for detected proteins. The upper 95% range was chosen for all data analysis and, within that cutoff, a total of 2,568 proteins consisting 38,786 distinct peptides were identified from 171,862 spectra (Table 1). An average of 5.89 peptides was matched per protein with an average of 13.88% sequence coverage from the total cohort of the detected proteins. The total number of proteins identified by a single peptide match was 980 proteins from the 2,568 identified which is approximately 37% of identified proteins. The analysis cut off removed proteins with below the average peptides matched (i.e. 5 peptides/protein) to increase the robustness of the dataset and the conclusions drawn. A table of all of the above proteins is available in supplementary material 1A. The subsequent cut offs utilised were based on p-value (<0.05) and fold change (log2< −0.2 or 0.2>). These partitions refine the later analyses to statistically significant proteins which have an average of 20 matched peptides per protein. The ProteinPilot group file, the protein summaries and peptide summary (without background corrections) were exported to XML format for further analysis with specified denominators for inter-sample comparisons through the generation of volcano plots and gene ontology graphs.

Volcano plots were generated to visualise the up/down regulated proteins, showing p-values versus the log2 protein fold change of each experimental cell line vs. Basal hADSCs of all 2,568 proteins. The quantitation criteria cut off of significant protein fold changes were completed statistically with the students t-test at p-values of <0.05 and log2 fold change cut off of −0.2 or >0.2. This found 2,418 proteins were directly comparable between any two sample types at a time (Fig. 2A~C). The blue nodes outside the horizontal and vertical asymptotes represent the statistically significant changed proteins above >0.2 log fold change up-regulated proteins and the below <0.2 fold change down-regulated proteins. The grey nodes represent the non-significantly changed proteins with a p-value > 0.05 and within the cut off for fold change.

The number of statistically significant up and down regulated proteins from each fold comparisons between 12 hr differentiated vs ADSCs (115v114) revealed 81 up regulated and 171 down regulated (Fig. 2A) proteins, comparisons between 24 hr differentiated vs ADSCs (116v114) revealed 85 up regulated and 138 down regulated proteins (Fig. 2B), and comparisons between GBCs vs ADSCs (117v114) revealed 429 up regulated and 504 down regulated proteins (Fig. 2C).

Fig. 2D exhibits the ratio of statistically changed proteins across all samples compared to basal ADSCs in the form of a bar graph. The blue bar presents non-statistically significant changed proteins, red bar is the statistically significant up regulated proteins and green is the statistically significant down regulated proteins.

The Venn diagrams in Fig. 3 presents the statistically relevant up/down regulated proteins that are unique and shared between each time point and the control cell line. Table 2A and 2B presents the up and down regulated proteins respectively. The data listed shows the unique and common proteins to each differentiation time point and their statistical significance as well as fold change relative to the ADSCs. Furthermore the table also shows the relative fold change and p-value of proteins in the other time points to present the extent of change in expression of proteins between the time points. Table 2C presents important proteins related to neurogenesis by cell proliferation, cell differentiation, morphogenesis, cytoskeleton remodelling or response to stress or shock by function according to Gene Ontology biological processes. The mutual expression of neurogenic and stress related proteins indicates the cells are experiencing a directed push toward a phenotype expressing neuronal proteins however the stress proteins indicate that the chemical differentiation is traumatic to the cells and is damaging them throughout the process.

The down regulation of significant numbers and types of cytoskeletal related proteins, such as actin and tubulin proteins, in the 12 and 24 hr differentiated ADSCs to levels consistent with the GBCs indicates a large morphological restructuring of the cell as identified during microscopy, or damage. The relatively large decrease in myosin related proteins in both differentiation time points indicates that the differentiating cells have shifted away from a mesodermal lineage. This trend is further supported by the mass down regulation of pro-collagen and collagen related structural proteins which, when in high abundance, play a pivotal role in connective tissue, adipose, cartilage and bone formation. Conversely a down regulation of similar structural support proteins is also an indication of cellular damage and stress which has been noted to occur in acute epithelial cell injury (14), and this is covered further in the discussion.

A decrease in the enzyme alpha enolase and the relative increase in gamma enolase/NSE levels are consistent with the development of neuronal tissue seen in rats and humans (15). A switch from alpha enolase, which is mesodermal specific, to gamma enolase which is ectodermal/neuronal specific is often used as an enzymatic biomarker for neuronal development (16). The levels of alpha enolase detected in the differentiation time points are equivalent to the GBC cell line. However, the detected levels of up regulated NSE within the differentiated and GBCs lies in the non-statistically significant identified proteins.

Western Blots

The majority of the aforementioned proteins have more than 5 unique positively matched peptides (Supplementary Table 1). This larger list of neuronal related proteins were deemed to be important and required further investigation as three out of the four most widely used markers for neurogenic differentiation (46), Neuron specific enolase (NSE), Neudesin (NENF) and Beta-tubulin III (βT3) fell within this statistically non-significant, up regulated neuronal related protein cut off group. The fulfillment of the 5 peptides or greater cut-off suggests that these molecules are changing but not statistically significantly. Western blots to detect the commonly used neuronal markers βT3, GFAP, NF200 and NeuN were carried out to compare these protein’s expression in the BME treated ADSCs with GBC whole cell lysates in this study and previous literature. βT3 is a 55 kDa protein which is positively detected in the basal ADSCs, the BME differentiated ADSCs and the GBCs (Fig. 4A). The GFAP molecule is only detected at the 48 kDa mark in the GBC lane at a normal exposure (Fig. 4B). By decreasing the contrast by 20%, the GFAP is just detectable in the BME differentiated cells. The NF200 protein is detected in both the ADSC differentiated and with a slightly stronger presence in the GBC at 200 kDa while there is no trace present in the BME lane (Fig. 4C). The NeuN however was not detected in the ADSCs but very faintly in the BME differentiated and GBCs (Fig. 4D). βT3 has been used to characterise primitive neuroepithelium and catalogued as being solely expressed on neuronal cells (17) however βT3 has been found to be expressed in the ADSCs within this study. Similarly the presence of NeuN in the ADSCs confounds the use of this protein as a neuronal specific marker. Thus the identification and quantitatation of the extent of differentiation with relatively few markers is insufficient thus supporting the wider proteomic analysis.

Cell Counts

The total cell count and average cfu/mm2 trends (Fig. 5) are identical presenting no change in cell population in the triplicate flasks from basal cells up to 1 hr post induction. The basal population counts averaged at 77 cfu/mm2 or total population of 5.42E+06 cells. Subsequent to the BME treatment the population decreases by approximately 18% to 63 cfu/mm2 by the 5 hour time point. After 20 hours the cell population decreases by 46%, to 35 cfu/mm2, relative to the basal cells (Fig. 5). Upon harvest of the final time point the total dead/live ratio was 1:9 i.e. an average of 10% of cells were stained blue with trypan.


The Bioplex assay is an efficient system for examining up to 27 cytokines across multiple sample types simultaneously, revealing quantitative changes and relative concentrations of these secreted molecules. Media that the cells were growing in were collected and analysed from the differentiation time points 0, 1, 3, 5, 20 and 24 hours. A hierarchical clustering and Euclidean test in the DanteR software were used to cluster the multiple data points in a heat map configuration where red represents expression above median; green: expression below the median and Black: median expression across all samples (Fig. 6). The hierarchical clustering (Fig. 6) presents the cytokines with similar concentration trends over the differentiation time points.

Cytokines, while having their unique roles in metabolic and cellular processes, can often be regulated in synchrony or regulate the expression of other cytokines in MSCs (18). Individually and collectively their relative concentrations can be related to particular cellular events. As such a number of trends occur within the Bioplex temporal differentiation data set. The molecules IL-1ra, Eotaxin, IL-2 and Rantes share a uniform trend in this dataset with similar concentration fluctuations between IL-1ra and Eotaxin which are comparable to IL-2 and Rantes. The trend reveals the highest concentration of the respective molecules is present at the 0hr time point, with a uniform decrease to the lowest concentrations at the 1 hr time point. This is followed by a slight recovery at the 3rd through the 5th hr. The concentration decreases fractionally again at the 20th hr for IL-1ra and Eotaxin then stabilises at the final time point The next group of trend related cytokines were composed of IL-4, IL5, IL-9, MIP-1a and MIP-1b which followed a fairly simple and distinct trend. The highest concentration occurs at time point 0hrs which then decreases by approximately 75% for all five cytokines thereafter and remains comparatively at the similar concentrations for all time points, with a minor recovery at 3 hrs post induction (Supplementary Table 2). The group consisting of IL-7, IL-13, PDGF-bb, TNF-a, MCP, IFN-g have a somewhat similar trend to the previous group, in that the highest concentrations occur at time point 0hrs, the major defining trend for this series is the significant decrease in concentration to less than 10% in the next time point which is maintained over the course of the differentiation time showing a marginal increase at the 24 hour mark (Supplementary Table 2). The following group: IL-8, IL-10, IL-12, G-CSF and VEG-F also share some common features with the previous two groups in that the highest concentration is observable at time point 0 hrs. The difference is the substantial decrease to near non-detectable concentrations for the entirety of the differentiation (Supplementary Table 2). Conversely the two remaining cytokines IL-6 and FGF were grouped together due to their unique trends that appear to be somewhat related. The main difference between these trends in these two cytokines is that IL-6 appears to have a concentration below the detectable level at time point 0 hrs whereas FGF has approximately 42 pg/ml at the same time point. The trends display a somewhat similar trait after 1 hour with increasing concentrations in both cytokines with the highest levels at the final two time points (Supplementary Table 2).


In this study, we investigated hADSCs ability to transdifferentiate toward a neuronal-like lineage within 12 and 24 hours, as well as the changes in the proteome occurring during the differentiation process. It was found that the cells responded to BME differentiation media with similar morphological and marker profiles as previously reported (4, 5, 19) and several groups of proteins involved in neural growth and protection were identified by MS/MS analysis. We also found the acquired soluble proteome of hADSCs differentiated for 12 hours and 24 hours to be noticeably different from basal ADSCs and GBCs, presenting a number of fold changes in proteins related to neuronal differentiation, cytoskeletal remodeling as well as an array of stress response proteins. Furthermore Bioplex cytokine profiles present evidence of a large cellular remodeling shift and stress response activity during the induced differentiation process which is reflected in the proteomic data sets. This study reveals that the BME treatment of ADSCs toward a neurogenic lineage presents a wide array of neuronally related proteins and morphology however the extended exposure of BME to the cells induces a significant stress response.

As demonstrated in this work, the secreted material can be analysed via iTRAQ proteomics or Bioplex cytokine analysis for definitive profiling. Several stress and shock related proteins were identified (Table 2). The proteins Heme oxygenase, Glutamate--cysteine ligase regulatory subunit (GCLM), Glucose-6-phosphate 1-dehydrogenase (G6PD), Prostaglandin G/H synthase 1 (PTGS1), Heat shock protein beta-11 (HSPB11), Stress-70 protein (HSP-70), Keratin, type II cytoskeletal 1, Heat shock protein beta-1 (HSPB1) and 10 kDa heat shock protein (HSPE1), mitochondrial were all investigated to ascertain their role during induction as they were statistically significantly up regulated stress related proteins at the various time points.

The expression of Heme oxygenase (HO) in neurogenic induced ADSCs is an interesting finding since its primary function is the degradation of heme producing biliverdin, iron and carbon monoxide (20). The expression of HO has been found in lung epithelial and liver cell types experiencing oxidative stress (21, 22). Furthermore HO has annotated roles in the response to the action of the oxidative stress linked proinflammitory cytokines IL-1B and TNF-α in astroglial cells (23). It has also been found that HO and the proinflammatory cytokines play a protective role in neuronal cells experiencing oxidative stress as neurons over expressing HO are resistant to oxidative stress mediated cell death (24). The Bioplex results exhibited the expression of IL-1B and TNF-α was far too low for a discernible concentration to be calculated for the former and very low concentrations for the latter to elicit a proinflammatory affect (25). The expression of HO in neurogenic induced ADSCs is undoubtedly due to oxidative stress however the prevention of cell death was not apparent (Fig. 1). Its use as a potential marker indicating cellular distress and protection against oxidative induced death is useful in future studies to indicate stress in chemical inductions (24).

The expression of GCLM has also been linked to a response to oxidative stress; however it has also been detected in high concentrations in muscle cells and lung epithelium undergoing hypoxic or oxidative stress (26). Some studies have linked GCLM to improving the antioxidative defense in astroglial cells by enhancing hydrogen peroxide scavenging ability however this was also in the presence of a thyroid hormone (27), and modulation of the survival of astrocytes and neurons in the presence of reducing agents (28).

Similarly, the high expression of G6PD, like many of the other proteins in this cohort, has been linked to the oxidative stress response by maintaining a redox imbalance-induced apoptosis in a number of cell types (29). Studies in Parkinson’s disease relating oxidative damage to neuronal cells in transgenic mice have shown a moderate increase in G6PD activity and an over expression and neuroprotective activity in aged animals (30).

Equally PTGS1 has been annotated by gene ontology to promote neuronal development and be induced due to oxidative stress. The mechanisms of which PTGS1 is expressed as a neuronal support protein or stress related protein are in response to different signals. The link PTGS1 has to neuronal development is directly associated with the moderate expression of the proinflammatory cytokines IL-1B and TNF-α (31), which in this study has been previously mentioned to have near undetectable concentrations. Studies into their expression during oxidative stress has shown a high expression of PTGS1 from various cell types in the presence of DMSO (32) which incidentally has also been used as an analogous neurogenic induction chemical (3, 4, 7).

Chemically induced oxidative stress to cells has been linked to inhibiting the COX-1 and COX-2 gene which directly affects the proliferation of cells and the high expression of PTGS1 (33). Our findings and the supportive literature indicates that the ADSCs treated with BME neurogenic induction media are responding in a similar manner to other cells types experiencing an overexposure to chemicals which cause an imbalance to the redox state in cells.

Further, to the detected oxidative stress proteins, a variety of additional stress and shock related proteins were noteworthy to this study. HSPB11, which has been linked to an inflammatory response in certain diseases (34), was found to be uniquely and highly expressed in the 24 hour induced ADSCs with none of its ten annotated interacting partners detected in our datasets. Minimal literature is available on the investigation of HSPB11’s role in the stress response. Its presence in the induced ASDCs cannot be accounted for except in response to inflammatory cytokines or due to the oxidative stress experienced by the cells.

HSP-70 is a widely studied heat shock protein and has been found to be ubiquitously expressed in all organisms, linked to the control of cellular proliferation and maintenance during aging (35). One study into homologous stress related proteins in Mytilus edulis have shown a differential in temperature determines the level and sites of expression of stress-70-like proteins in tissue (36). The over expression of HSP-70 has also been linked to the cell’s response to toxic chemicals and the development of cancerous growth (37). The purpose of HSP-70 is postulated to be involved in the protection of cells under thermal or oxidative stress by inhibiting the aggregation of damaged and unfolded proteins (38).

Similarly, HSPB1 and HSPE1 expression is increased when cells are in distress which includes thermal, physical and chemical stressors (Table 2) (39). They are functionally similar to the HSP-70, also annotated in the inhibition of aggregating, damaged or stressed proteins (40). Thus the high expression of heat shock proteins reveals that the ADSCs are being exposed to a prolonged period in traumatic, stress inducing conditions.

Numerous of the above stress related proteins have been linked to the maintenance or protection of neuronal cells experiencing oxidative stress, the remaining shock induced proteins are not related to neuronal cells and are dually expressed due to the extensive stress. While these proteins functions are to preserve the cells in this environment, the loss of approximately 50% of the cell population is alarming and indicates that the surviving cells expressing the detected proteins may in fact be damaged by the induction process.

A shorter treatment may initiate the induction toward a neurogenic differentiation, as an exposure of more than 12 hours to the BME containing media is a stress inducing environment. Our findings essentially indicate that the produced cells may have had the potential for neurogenic differentiation due to the wide variety of neuronal related proteins expressed and detected. However the high abundance of up regulated stress related proteins and high cell death indicates the cells are being damaged. This suggests the culture conditions for inducing ADSCs toward a neurogenic linage with BME is not conducive to producing complete neuronal cells. Nonetheless, the process and mechanisms which drives the cells to differentiate is the most important result acquired as this could be mimicked with much milder and non-toxic chemical cocktails.


The use of chemical inducers to initiate neurogenesis has become well accepted because of its simplicity and due to its relatively rapid outcome of producing morphologically neuronal-like differentiated cells compared to the alternative growth factor induction methods. It is important that the choice of chemical inducer is not toxic to the cells to the extent that major cell death is apparent. While the use of BME produces interesting results in the induction of neurogenesis in ADSCs, it is quite toxic to cells and therefore would not be useful in a clinical setting. This is reflected in decrease in total cell population within the 24 hours of induction. The high death rate in the BME neurogenic induction would not be permissive for in vivo treatments, especially since the extent of damage or stress to the surviving cells has not been well characterised. A catalogue of stress proteins and potential markers can be useful in identifying the biological processes initiated during induced neurogenesis when utilising alternative chemicals to BME.


We would like to thank the Australian Proteome Analysis facility (APAF), Macquarie University, Thiri Zaw and Cameron Hill for technical support.

Supplementary Information
Fig. 1. Morphological comparisons between non-induced ADSCs and chemically induced ADSCs. (A) Basal human ADSCs cultured as a control prior to differentiation presents standard flat fibroblastic morphology. (B~D) hADSCs post induction 3 hours, 12 hours and 24 hours with neurodifferentiation media with the progressive structural remodelling over the 24 hour time period. 10×Magnification.
Fig. 2. Volcano plots. (A~C) showing p-values versus protein fold change (log2) of ADSCs and comparisons. Quantitation criteria cutoff of statistically significant p-values <0.05 and log2fold change cutoff of <−0.2 or >0.2. The blue nodes represent the above >0 log fold change i.e. up-regulated proteins and the below <0 fold change down-regulated proteins. The grey nodes represent the not significantly changed proteins with a p-value >0.05 and within the cut off for fold change. D shows the ratio of statistically changed proteins across all samples compared to basal ADSCs. Blue bar presents non-statistically significant changed proteins, red bar is the statistically significant up regulated proteins and green is the statistically significant down regulated proteins.
Fig. 3. Three-way Venn diagrams of up and down regulated proteins. Diagrams include the 12 hour differentiated, 24 hour differentiated hADSCs and the GBCs showing unique and shared proteins. (A) shows up regulated proteins revealing there are 29, 26, 357 unique proteins with 11, 32 and 25 shared proteins between each of the corresponding tested cell lines as well as 16 shared proteins between all three relative to basal hADSCs. (B) shows down regulated proteins revealing there are 36, 26, 364 unique proteins with 19, 27 and 50 shared proteins between each of the corresponding tested cell lines as well as 66 shared proteins between all three relative to basal hADSCs.
Fig. 4. (A) Western blot of BT3 positive in ADSCs, BME differentiated and GBCs seen at 55 kDa. (B) GFAP positively detected in GBCs at 48 kDa. (C) NF200 positively identified at 200 kDa in GBCs and very weakly in ADSC. (D) NeuN a very low positive in BME differentiated and GBCs. −VE is a negative control of a whole cell lysate of an unrelated cell line.
Fig. 5. Average total cell count at each time point over the BME treatment of ADSCs with mean error bars. Average cell count shows the total number of cells at each time point with drastic decreases in the final two points.
Fig. 6. Bioplex 27-plex cytokine array of ADSCs treated with BME over time. Bioplex comparisons of interleukins and cytokine secretions from basal ADSCs and temporal differentiation with BME neuronal differentiation media. Hierarchical clustering software and Euclidean test Red: expression above median; Green: expression below the median; Black: median expression across sample.
Table. 1.

Mass spectrometry iTRAQ protein and peptides counts with relative cutoffs of ADSCs, ADSCs differentiated for 12 hours and 24 hours and glioblastoma cells protein pilot results

Confidence cutoffProteins detectedProteins before groupingDistinct peptidesSpectra identified% total spectra
>2.0 (99)220329483737016963066.8
>1.3 (95)256835053878617186267.7
>0.47 (66)288654104020917393568.5
Cutoff applied: >0.05 (10%)3760163154334717819770.2

Table. 2.

Up regulated proteins identified in Volcano plots with fold change and p-values relative to ADSCs. The table also includes the data for the same protein in all other samples showing its relative fold change and p-value in that respective sample

Accession and gene nameProtein name12 hr:ADSC fold change12 hr:ADSC p-value24 hr:ADSC fold change24 hr:ADSC p-valueGBC:ADSC fold changeGBC:ADSC p-value
Proteins only in 12 hr differentiation
 sp|Q09666|AHNK_HUMANNeuroblast differentiation-associated protein AHNAK1.1722919949.64E-210.9325047140.00073910.2843767110
 sp|Q14697|GANAB_HUMANNeutral alpha-glucosidase AB1.1662130360.0005111391.0702400210.2228115050.5898606189.70205E-08
 sp|O94979|SC31A_HUMANProtein transport protein Sec31A1.1634279490.0086233810.9572051170.2830387060.4923309981.42785E-07
 sp|P34897|GLYM_HUMANSerine hydroxymethyltransferase, mitochondrial1.2296350.0002595591.0086829660.8523252010.860659480.003069297
 sp|O94925|GLSK_HUMANGlutaminase kidney isoform, mitochondrial1.1672049760.0232153590.8882923720.2453193070.6111546750.00079499
 sp|Q92616|GCN1L_HUMANTranslational activator GCN11.2235349420.038583831.0145540240.782537520.7670043110.036446411
 sp|P16152|CBR1_HUMANCarbonyl reductase (NADPH) 11.1740609410.0268518111.1276559830.0753134490.434437997.23315E-05
 sp|Q3SY69|AL1L2_HUMANMitochondrial 10-formyltetra-hydrofolate dehydrogenase1.1980429890.0246661810.9339032770.4956105950.2209725981.12357E-05
 sp|P16070|CD44_HUMANCD44 antigen1.2913949490.004412531.0328010320.6272367840.5474898220.01207258
 sp|Q16666|IF16_HUMANGamma-interferon-inducible protein 161.1717519760.0463274611.1453590390.0427937280.5415732860.00104327
 sp|Q12797|ASPH_HUMANAspartyl/asparaginyl beta-hydroxylase1.2431449890.0037299931.0053509470.9365277890.7124413850.01231128
 sp|O94855|SC24D_HUMANProtein transport protein Sec24D1.1889679430.0448531511.0130729680.8300204870.4289467930.00079677
 sp|O75533|SF3B1_HUMANSplicing factor 3B subunit 11.2942850590.029792461.0957130190.310032010.9249290820.493676394
 sp|P12111|CO6A3_HUMANCollagen alpha-3 (VI) chain1.3346689940.0003428440.8098701830.0016985970.3830687110.001706147
 sp|P09601|HMOX1_HUMANHeme oxygenase 12.308733940.0003301151.0186100010.7997279170.4356690940.00274237
 sp|Q15459|SF3A1_HUMANSplicing factor 3A subunit 11.2212049960.0062488121.1273519990.1079623031.2066220050.062194299
 sp|P09619|PGFRB_HUMANPlatelet-derived growth factor receptor beta1.1900860070.046704460.7414320110.057049770.2647672890.019523449
 sp|Q92841|DDX17_HUMANProbable ATP-dependent RNA helicase DDX171.2186110020.022521631.040665030.5381566881.0760159490.290756613
 sp|Q04828|AK1C1_HUMANAldo-keto reductase family 1 member C11.8092620370.0009059881.4388120170.0847179670.9919846060.936510086
 sp|Q5SSJ5|HP1B3_HUMANHeterochromatin protein 1-binding protein 31.410802960.013535181.1917179820.1508235930.806796730.250696898
 sp|Q9BUJ2|HNRL1_HUMANHeterogeneous nuclear ribonucleoprotein U-like protein 1 11.2379629610.0075580461.133013010.1444370.7190043930.034528211
 sp|P55263|ADK_HUMANAdenosine kinase1.1996330020.042127711.1842559580.1183302030.7167798280.024615809
 sp|A1X283|SPD2B_HUMANSH3 and PX domain-containing protein 2B B1.2736090420.018672281.1113109590.1698784980.9397165180.643383682
 sp|Q14914|PTGR1_HUMANProstaglandin reductase 11.2725609540.0427434110.9163267020.4756124020.3368287090.016600359
 sp|P50281|MMP14_HUMANMatrix metalloproteinase-141.3390970230.04134941.1989220380.10134650.8056157830.137749895
 sp|P49792|RBP2_HUMANE3 SUMO-protein ligase RanBP21.352550030.008359171.0889070030.3963473141.1589119430.221689299
Common proteins in 12 and 24 hour differentiation
 sp|P13010|XRCC5_HUMANX-ray repair cross-complementing protein 51.1499520540.0005218661.2358649970.0015665131.0621320010.196620807
 sp|P78527|PRKDC_HUMANDNA-dependent protein kinase catalytic subunit1.1859110592.83388E-051.2047920236.77829E-071.0860810280.068069547
 sp|P04181|OAT_HUMANOrnithine aminotransferase, mitochondrial1.2970759870.0004005321.2294429540.002146910.7993357780.036058169
 sp|Q9NVI7|ATD3A_HUMANATPase family AAA domain-containing protein 3A1.3822699790.0241065811.3442679640.0461134990.764913380.144031405
 sp|Q13740|CD166_HUMANCD166 antigen1.2924499510.010250221.4133019450.0005947831.0023280380.9778862
 sp|Q1KMD3|HNRL2_HUMANHeterogeneous nuclear ribonucleoprotein U-like protein 2 21.1634310480.0257919691.1623640060.0376567280.6875373130.01868871
 sp|P22307|NLTP_HUMANNon-specific lipid-transfer protein1.1812080140.010803291.5068000568.88028E-050.8172672990.067778051
 sp|P02792|FRIL_HUMANFerritin light chain5.8414301870.0001733941.2894840240.023081021.0648649930.623959184
Proteins only in 24 hour differentiation
 sp|P11021|GRP78_HUMAN78 kDa glucose-regulated protein0.9789155720.7325819731.2255580432.06624E-080.4651849874.34353E-08
 sp|Q01813|K6PP_HUMAN6-phosphofructokinase type C0.992663980.8576604131.1571060420.0216281690.3781340123.5279E-07
 sp|P11940|PABP1_HUMANPolyadenylate-binding protein 11.0063760280.9359158871.1728310590.014077690.8100705740.001010054
 sp|O60701|UGDH_HUMANUDP-glucose 6-dehydrogenase0.9566413160.3199549911.1635940070.015034780.2687839877.86066E-08
 sp|Q8NBS9|TXND5_HUMANThioredoxin domain-containing protein 50.9857934710.7513123751.2189619540.0061991350.5472866891.33254E-07
 sp|P14314|GLU2B_HUMANGlucosidase 2 subunit beta1.071501970.2018803061.2302839760.0027287040.7874907260.00148304
 sp|P26640|SYVC_HUMANValine--tRNA ligase1.0608710050.11737291.1497089860.016084381.0074839590.905321598
 sp|P62249|RS16_HUMAN40S ribosomal protein S160.8582360150.0042911361.2110660080.002401640.7129008771.01167E-05
 sp|P61019|RAB2A_HUMANRas-related protein Rab-2A1.0651190280.2174825071.1626900430.010667141.0800780060.288548201
 sp|P62750|RL23A_HUMAN60S ribosomal protein L23a0.6930984850.000864171.1890590190.017037580.4874162970.000572545
 sp|Q00325|MPCP_HUMANPhosphate carrier protein, mitochondrial1.1011600490.2770841121.2857209440.0002417250.8331416250.028220629
 sp|P42765|THIM_HUMAN3-ketoacyl-CoA thiolase, mitochondrial1.1738990550.0535170991.2349250320.0019658760.34276250.000915591
 sp|P23219|PGH1_HUMANProstaglandin G/H synthase 11.1034649610.1514140961.2167880540.0024850030.2393939050.000434135
 sp|P31942|HNRH3_HUMANHeterogeneous nuclear ribonucleoprotein H31.0386960510.7306650281.2529380320.0150921.1229339840.502929688
 sp|P51572|BAP31_HUMANB-cell receptor-associated protein 310.8482664230.1393595041.2636059520.018130790.5784804229.32726E-05
 sp|P24534|EF1B_HUMANElongation factor 1-beta1.0268429520.7335755231.2097489830.018797420.7087317110.023696421
 sp|P62851|RS25_HUMAN40S ribosomal protein S250.7520574930.021064221.2572619920.0216226390.6406930090.028522549
 sp|P13645|K1C10_HUMANKeratin, type I cytoskeletal 101.0201380250.8824434281.4689240460.0205493491.6157920360.058578409
 sp|P02768|ALBU_HUMANSerum albumin0.6074749230.0837860115.5043230060.0052267250.7308366890.622102082
 sp|Q00765|REEP5_HUMANReceptor expression-enhancing protein 50.7900621890.21312351.4263520240.027967190.3621382120.040924039
 sp|Q6PIU2|NCEH1_HUMANNeutral cholesterol ester hydrolase 10.9339436890.6032599211.3017209770.0372617991.2510429620.191826195
 sp|Q15382|RHEB_HUMANGTP-binding protein Rheb1.0325130220.622737111.221518040.0320018011.2284669880.154868901
Common proteins in 24 hour differetiation and GBCs
 sp|P38646|GRP75_HUMANStress-70 protein, mitochondrial1.1170779470.0031314881.1528790.0003090531.6590199472.0803E-08
 sp|P06576|ATPB_HUMANATP synthase subunit beta, mitochondrial1.1340680120.012577571.2436970470.0068406081.5236179838.35058E-08
 sp|P21796|VDAC1_HUMANVoltage-dependent anion-selective channel protein 11.0038729910.953147591.2220740320.010488611.7964160441.28039E-07
 sp|Q15233|NONO_HUMANNon-POU domain-containing octamer-binding protein1.0901730060.3906207981.1580530410.0250607211.5852350.00078185
 sp|P05141|ADT2_HUMANADP/ATP translocase 2 SV=71.0996500250.2387592941.3794879910.0462000892.1268179420.003026843
 sp|P29692|EF1D_HUMANElongation factor 1-delta0.8856608870.2953358891.2195990090.0180109111.4241820570.001063915
 sp|P16401|H15_HUMANHistone H1.5 B1.1395100360.4677948061.3770780560.0012854382.0524940490.000144169
 sp|P45880|VDAC2_HUMANVoltage-dependent anion-selective channel protein 21.1323659420.029729771.4909789560.0003772961.4147750142.3224E-05
 sp|P07910|HNRPC_HUMANHeterogeneous nuclear ribonucleoproteins C1/C20.9717311860.7176812291.2867009640.026253242.4336969853.47498E-06
 sp|P62807|H2B1C_HUMANHistone H2B type 1-C/E/F/G/I BC1.228741050.19672511.673745990.014493052.9937949180.004183407
 sp|P09429|HMGB1_HUMANHigh mobility group protein B10.9889820810.8818070891.2026000020.042946453.0862939360.000200443
 sp|Q07955|SRSF1_HUMANSerine/arginine-rich splicing factor 11.0951069590.2658653861.2019389870.004240191.7687419653.07727E-05
 sp|P04264|K2C1_HUMANKeratin, type II cytoskeletal 11.1659820080.0789020211.2779539820.012470191.7125619658.00445E-05
 sp|P61604|CH10_HUMAN10 kDa heat shock protein, mitochondrial1.0328459740.7868816261.4252259730.0005079184.025928020.000107939
 sp|P54819|KAD2_HUMANAdenylate kinase 2, mitochondrial1.1840109830.0898303461.1596959830.04102282.8500180240.000481253
 sp|P48047|ATPO_HUMANATP synthase subunit O, mitochondrial1.2061400410.1210995991.2403399940.0072401692.9757819183.41347E-06
 sp|P30040|ERP29_HUMANEndoplasmic reticulum resident protein 291.1328409910.0891528871.3042399880.0041584781.9056060314.23384E-05
 sp|P55809|SCOT1_HUMANSuccinyl-CoA:3-ketoacid-coenzymeA transferase 1, mitochondrial1.086030960.3841350081.1688380240.035602891.9130940447.59599E-05
 sp|P30048|PRDX3_HUMANThioredoxin-dependent peroxide reductase, mitochondrial1.1406010390.2057787031.3088979720.032524911.4766889810.01063342
 sp|O43615|TIM44_HUMANMitochondrial import inner membrane translocase subunit TIM441.2608749870.1493179951.352136970.0198517111.5889869930.02601867
 sp|P20674|COX5A_HUMANCytochrome c oxidase subunit 5A, mitochondrial0.9554967880.5329720971.4324239490.0031533572.3075850010.001240918
 sp|P62316|SMD2_HUMANSmall nuclear ribonucleoprotein Sm D21.0985269550.2028329071.1868239640.0424210391.3495479820.003658696
 sp|P53999|TCP4_HUMANActivated RNA polymerase II transcriptional coactivator p151.0863300560.2119818031.2672100070.0072589071.4880839590.000537378
 sp|P10606|COX5B_HUMANCytochrome c oxidase subunit 5B, mitochondrial0.8485546110.1211595981.3430629970.014809791.8916779760.000901474
 sp|O75964|ATP5L_HUMANATP synthase subunit g, mitochondrial1.1722619530.1877232041.406666040.008250821.6561650040.035087962
 sp|O96000|NDUBA_HUMANNADH dehydrogenase (ubiquinone) 1 beta subcomplex subunit 101.112455010.2309816931.3193320040.0060977321.6631089450.00063837
 sp|P13073|COX41_HUMANCytochrome c oxidase subunit 4 isoform 1, mitochondrial0.8881943230.1942325981.3139300350.0221940891.5924390550.007572151
 sp|Q13217|DNJC3_HUMANDnaJ homolog subfamily C member 31.2338550090.0544941391.1539009810.025614071.3943140510.007471726
 sp|Q04837|SSBP_HUMANSingle-stranded DNA-binding protein, mitochondrial1.1378159520.1292548031.3359869720.010212532.8946259020.000223126
 sp|Q00059|TFAM_HUMANTranscription factor A, mitochondrial1.0924409630.2540710871.1990000010.0448622112.6391310690.001804102
 sp|P56385|ATP5I_HUMANATP synthase subunit e, mitochondrial1.1764030460.1620361951.5219490530.010311771.9128400090.025020519
Common proteins in 12 hour differentation and GBCs
 sp|P14136|GFAP_HUMANGlial fibrillary acidic protein1.1543109420.01318980.7408100960.14921650355.99203117.59313E-15
 sp|Q14195|DPYL3_HUMANDihydropyrimidinase-related protein 31.1916569470.0047375610.8287724260.0646210169.3925514221.8213E-06
 sp|P42330|AK1C3_HUMANAldo-keto reductase family 1 member C31.3753559590.0407214090.9035208230.6528267266.7575259210.00714481
 sp|P48735|IDHP_HUMANIsocitrate dehydrogenase (NADP), mitochondrial1.1873539690.0016260350.760787010.002227614.9582028393.07282E-11
 sp|P55084|ECHB_HUMANTrifunctional enzyme subunit beta, mitochondrial1.2074409720.0013590621.1206840280.021999261.5462490321.85189E-07
 sp|P40939|ECHA_HUMANTrifunctional enzyme subunit alpha, mitochondrial1.2041389940.0010256851.0995990040.0513748011.2169220450.01704336
 sp|O75367|H2AY_HUMANCore histone macro-H2A.11.1937299970.0015477371.194239020.0817748231.9354900129.13986E-08
 sp|P30084|ECHM_HUMANEnoyl-CoA hydratase, mitochondrial1.197185040.0038887541.147070050.016787464.2529802321.23704E-05
 sp|P49591|SYSC_HUMANSerine--tRNA ligase, cytoplasmic1.193133950.012924621.0444999930.5041226151.8165329690.000177273
 sp|P62805|H4_HUMANHistone H4 A1.4477889549.72893E-051.5216749910.1039130992.2277228830.000899077
 sp|P15559|NQO1_HUMANNAD(P)H dehydrogenase (quinone) 11.6540139910.001399861.0196089740.7576801784.6437082296.49148E-05
 sp|O75874|IDHC_HUMANIsocitrate dehydrogenase (NADP) cytoplasmic1.3523310420.002696731.1023999450.2191248981.197000980.049357109
 sp|O43809|CPSF5_HUMANCleavage and polyadenylation specificity factor subunit 51.1722309590.016962961.0338259940.6583039162.6180229192.83626E-08
 sp|P11177|ODPB_HUMANPyruvate dehydrogenase E1 component subunit beta, mitochondrial1.2338199620.010569230.9666650890.8422157172.4224851130.005875809
 sp|P15121|ALDR_HUMANAldose reductase1.1831690070.005275441.0350919960.6128429171.3239010570.01107216
 sp|P38159|RBMX_HUMANRNA-binding motif protein, X chromosome1.3451559540.0429869591.2516510490.0630341171.7429829840.006319256
 sp|P09661|RU2A_HUMANU2 small nuclear ribonucleoprotein A′1.1720260380.0328992011.1225340370.0936668071.9661220314.43474E-05
 sp|Q9UIJ7|KAD3_HUMANGTP:AMP phosphotransferase, mitochondrial1.2562149760.013423421.1112099890.2922581144.4406371122.46386E-05
 sp|Q9Y6C9|MTCH2_HUMANMitochondrial carrier homolog 21.2863700390.0199083411.1815350060.0751195181.6325639490.017359991
 sp|P48507|GSH0_HUMANGlutamate--cysteine ligase regulatory subunit1.4669330120.012855041.0851240160.3385025862.5365769860.001289886
 sp|Q9Y305|ACOT9_HUMANAcyl-coenzyme A thioesterase 9, mitochondrial1.3224829440.012660971.0629270080.3454455141.473713040.007995555
 sp|Q9BTT0|AN32E_HUMANAcidic leucine-rich nuclear phospho-protein 32 family member E1.246726990.0444910191.2672070260.1080906022.4649710660.000903143
 sp|P07602|SAP_HUMANProactivator polypeptide1.2304890160.0378386420.8990017180.4594467881.4349679950.033458289
 sp|Q2M2I8|AAK1_HUMANAP2-associated protein kinase 11.2626229520.0402709691.0392800570.5827841161.3303099870.03768494
Common proteins in 12, 24 hour differenttiation and GBCs
 sp|P25705|ATPA_HUMANATP synthase subunit alpha, mitochondrial1.2129859926.15987E-051.2374199630.001200722.0686628821.71718E-08
 sp|P40926|MDHM_HUMANMalate dehydrogenase, mitochondrial1.1861979960.0008780191.2696950442.80119E-054.9147782332.84338E-11
 sp|P34897|GLYM_HUMANSerine hydroxymethyltransferase, mitochondrial1.1530640130.018438361.1892869470.0008435552.347326041.77116E-10
 sp|P00505|AATM_HUMANAspartate aminotransferase, mitochondrial1.2658870220.0036812561.2503390310.0070354832.9557321071.33896E-07
 sp|P49748|ACADV_HUMANVery long-chain specific acyl-CoA dehydrogenase, mitochondrial1.3692719940.0001015881.3524800540.0012012822.5534830099.20537E-09
 sp|P52209|6PGD_HUMAN6-phosphogluconate dehydrogenase, decarboxylating1.5262579923.7424E-071.1675479410.0020435122.104243042.09408E-07
 sp|P36542|ATPG_HUMANATP synthase subunit gamma, mitochondrial1.2701770070.010719051.3357789520.0012593672.8297870166.42483E-05
 sp|O75947|ATP5H_HUMANATP synthase subunit d, mitochondrial1.1866480110.0220315611.2194190030.0388249492.7607750890.00011906
 sp|O43143|DHX15_HUMANPutative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX151.1593259570.0289229811.173442960.0471520091.4222919940.016296981
 sp|Q9Y277|VDAC3_HUMANVoltage-dependent anion-selective channel protein 31.3097440.0300494991.2779430150.0056691862.3998420240.001137988
 sp|P24539|AT5F1_HUMANATP synthase subunit b, mitochondrial1.3092160220.0249074011.5869179960.0066414872.336842060.00240706
 sp|P02794|FRIH_HUMANFerritin heavy chain7.5220818520.0015239731.4584120510.0097501492.7962279320.007973121
 sp|Q07021|C1QBP_HUMANComplement component 1 Q subcomponent-binding protein, mitochondrial1.2854830030.0467222711.4274250270.014921064.9388470650.006008915
 sp|P14678|RSMB_HUMANSmall nuclear ribonucleoprotein-associated proteins B and B′1.2141840460.038792011.2238199710.0290701091.3934370280.01111761

Table. 3.

Down regulated proteins identified in Volcano plots with fold change and p-values relative to ADSCs

Accession and gene nameProtein name12 hr:ADSC fold change12 hr:ADSC p-value24 hr:ADSC fold change24 hr:ADSC p-valueGBC:ADSC fold changeGBC:ADSC p-value
Proteins only in 12 hr differentiation
 sp|P04406|G3P_HUMANGlyceraldehyde-3-phosphate dehydrogenase0.84792770.00434220.89636110.05393651.296050.0126654
 sp|P62258|1433E_HUMAN14-3-3 protein epsilon0.73456690.00145790.78897160.05404872.70003891.51E-08
 sp|P63244|GBLP_HUMANGuanine nucleotide-binding protein subunit beta-2-like 10.78501130.00232911.0261480.71826480.92164090.2950645
 sp|P08238|HS90B_HUMANHeat shock protein HSP 90-beta0.75363950.01406550.8602310.11147350.99505550.9490238
 sp|P62701|RS4X_HUMAN40S ribosomal protein S4, X isoform0.75931420.00059351.1442680.25892181.11946590.2733781
 sp|P09651|ROA1_HUMANHeterogeneous nuclear ribonucleoprotein A10.73050180.00516221.1069360.38593832.08436110.0006238
 sp|P61247|RS3A_HUMAN40S ribosomal protein S3a0.8360740.0498751.037420.42890241.3201950.001181
 sp|Q9Y617|SERC_HUMANPhosphoserine aminotransferase0.78374980.00291190.88802330.1354781.0871130.2114475
 sp|P63104|1433Z_HUMAN14-3-3 protein zeta/delta0.77944080.04240380.82613150.17411351.97829793.104E-05
 sp|P08865|RSSA_HUMAN40S ribosomal protein SA0.74625290.00992221.0369080.54128390.99887930.9859492
 sp|P62937|PPIA_HUMANPeptidyl-prolyl cis-trans isomerase A0.76633120.00208651.0624390.37474872.01339790.0001145
 sp|Q13347|EIF3I_HUMANEukaryotic translation initiation factor 3 subunit I0.81219180.01026580.94629030.36182411.0186850.8342772
 sp|O75534|CSDE1_HUMANCold shock domain-containing protein E10.7715260.00349170.99002590.86154620.94558570.6485646
 sp|P30050|RL12_HUMAN60S ribosomal protein L120.8493110.02328841.07976310.20558260.81810120.0908025
 sp|P55786|PSA_HUMANPuromycin-sensitive aminopeptidase0.40953550.02089440.84985920.25182631.9409410.0009965
 sp|P02511|CRYAB_HUMANAlpha-crystallin B chain0.63435050.00321481.028560.6856861.2207650.0158245
 sp|P30044|PRDX5_HUMANPeroxiredoxin-5, mitochondrial0.70280210.03893680.82852660.10524970.85353190.1997427
 sp|P62328|TYB4_HUMANThymosin beta-40.49200070.03321980.86217680.25070351.2393860.4872846
 sp|P63220|RS21_HUMAN40S ribosomal protein S210.74810420.00843511.0526330.67238170.85750140.073444
 sp|P18085|ARF4_HUMANADP-ribosylation factor 40.68215330.02802650.91785790.792540.84633990.4097828
 sp|P18621|RL17_HUMAN60S ribosomal protein L170.61510120.03490461.0577250.54795870.60392990.0704918
 sp|Q9NR30|DDX21_HUMANNucleolar RNA helicase 20.7432780.00990990.96315840.84921830.53111440.0828007
 sp|P49773|HINT1_HUMANHistidine triad nucleotide-binding protein 10.79600010.01575610.93269810.50849931.86626990.0207274
 sp|Q96JY6|PDLI2_HUMANPDZ and LIM domain protein 20.77051690.01811840.87895780.35948430.54898060.0511937
 sp|P09669|COX6C_HUMANCytochrome c oxidase subunit 6C0.63793590.0133771.1162260.26169330.99254510.9516448
 sp|P30520|PURA2_HUMANAdenylosuccinate synthetase isozyme 20.76024390.03692080.90350710.27855470.89730220.4219353
 sp|P06493|CDK1_HUMANCyclin-dependent kinase 10.70859270.01634010.74247810.12001132.33152510.0133933
 sp|P00403|COX2_HUMANCytochrome c oxidase subunit 20.54740850.02290930.82130910.16866171.6865540.0307677
 sp|Q9H910|HN1L_HUMANHematological and neurological expressed 1-like protein0.76869390.03954840.91412120.24729081.11958690.4445185
 sp|Q13308|PTK7_HUMANInactive tyrosine-protein kinase 70.71760570.01552430.78068430.21957180.82028660.2265889
 sp|Q8N3F8|MILK1_HUMANMICAL-like protein 10.62909080.03178770.92761050.48222351.507210.0750358
 sp|Q96K17|BT3L4_HUMANTranscription factor BTF3 homolog 40.68921970.04860060.66077360.10858020.4964240.112247
Common Proteins in 12 and 24 hr differentiation
 sp|P06744|G6PI_HUMANGlucose-6-phosphate isomerase0.71936770.00062540.66721368.246E-052.24878911.036E-08
 sp|Q9NZU5|LMCD1_HUMANLIM and cysteine-rich domains protein 10.70716450.00047050.64011134.341E-082.2962832.267E-09
 sp|P60174|TPIS_HUMANTriosephosphate isomerase0.75016740.01135290.70459170.00040072.52718096.364E-08
 sp|P49588|SYAC_HUMANAlanine--tRNA ligase, cytoplasmic0.67954985.394E-050.57467373.913E-061.3712784.908E-05
 sp|P04792|HSPB1_HUMANHeat shock protein beta-10.56049510.00017620.74266770.02092711.5411720.0089136
 sp|P35222|CTNB1_HUMANCatenin beta-10.85958720.01280060.76113141.582E-050.83875570.1275463
 sp|P62979|RS27A_HUMANUbiquitin-40S ribosomal protein S27a0.50513080.01282110.69334230.04146751.4127290.1300915
 sp|P00966|ASSY_HUMANArgininosuccinate synthase0.67655130.00310440.63591190.00201932.3319083.533E-06
 sp|Q12841|FSTL1_HUMANFollistatin-related protein 10.76395530.03457350.56403650.01905331.0708240.5687613
 sp|P07437|TBB5_HUMANTubulin beta chain0.46181950.04991910.51354890.00621170.98215690.9072029
 sp|P17936|IBP3_HUMANInsulin-like growth factor-binding protein 30.54180740.00674580.40802580.00637090.31982670.0523204
 sp|P50579|AMPM2_HUMANMethionine aminopeptidase 20.76938730.04831930.68005650.01744580.9384770.4942554
 sp|O15427|MOT4_HUMANMonocarboxylate transporter 40.64680690.04973130.63958980.04775220.12736220.0785593
 sp|Q9BV57|MTND_HUMAN1,2-dihydroxy-3-keto-5-methylthiopentene dioxygenase0.51404720.0025010.40790440.0048412.02343010.0111199
 sp|Q92896|GSLG1_HUMANGolgi apparatus protein 10.65840180.00786190.58891620.00047740.81512520.1259657
 sp|P28300|LYOX_HUMANProtein-lysine 6-oxidase0.68295360.02624150.33480250.02579060.34270740.226561
Proteins only in 24 hr differentiation
 sp|Q16881|TRXR1_HUMANThioredoxin reductase 1, cytoplasmic1.03644390.36168070.82197410.00054930.93603110.1332849
 sp|P48735|IDHP_HUMANIsocitrate dehydrogenase (NADP), mitochondrial1.1873540.0016260.7607870.00222764.95820283.073E-11
 sp|P17858|K6PL_HUMAN6-phosphofructokinase, liver type0.87968980.47380320.80368540.00261580.79094610.1816241
 sp|P49411|EFTU_HUMANElongation factor Tu, mitochondrial1.1361110.03265020.78714620.00115921.9471576.357E-07
 sp|P30086|PEBP1_HUMANPhosphatidylethanolamine-binding protein 10.87311240.02119420.82837930.00385643.19457891.385E-07
 sp|P35237|SPB6_HUMANSerpin B60.88026790.17456260.82572620.00864060.98156520.7505975
 sp|P07339|CATD_HUMANCathepsin D1.0515280.43941750.81928810.01176871.5466840.0010593
 sp|Q92900|RENT1_HUMANRegulator of nonsense transcripts 10.91789290.21859510.85584820.0273990.80759690.0586372
 sp|P09960|LKHA4_HUMANLeukotriene A-4 hydrolase0.94372570.51295620.83970650.0494171.1602280.2741844
 sp|Q16822|PCKGM_HUMANPhosphoenolpyruvate carboxykinase (GTP), mitochondrial0.95288160.82488230.58428520.00013550.65041040.0637888
 sp|Q8N8S7|ENAH_HUMANProtein enabled homolog0.82741770.05715760.68308150.00697040.93189530.5751261
 sp|P07203|GPX1_HUMANGlutathione peroxidase 10.86243360.21535370.78663760.01863322.5874670.001527
 sp|P63092|GNAS2_HUMANGuanine nucleotide-binding protein G(s) subunit alpha isoforms short0.85574810.12827860.81804710.03245841.76060610.0025444
 sp|P68400|CSK21_HUMANCasein kinase II subunit alpha0.92400490.26561850.84571340.04446611.1055540.3466572
 sp|Q9BRK5|CAB45_HUMAN45 kDa calcium-binding protein0.56500940.12180790.53486250.00839421.2834820.052236
 sp|P08648|ITA5_HUMANIntegrin alpha-50.88279750.2835670.83341290.03902960.25928280.1002662
 sp|Q04760|LGUL_HUMANLactoylglutathione lyase0.87735580.14611250.7677110.0311372.817450.0119689
 sp|P25325|THTM_HUMAN3-mercaptopyruvate sulfurtransferase0.91394390.48998270.64357510.01768271.0333380.784981
 sp|Q8IVL6|P3H3_HUMANProlyl 3-hydroxylase 30.80731670.28686690.57314550.02640810.36689240.0672391
 sp|Q9HB07|MYG1_HUMANUPF0160 protein MYG1, mitochondrial0.88191750.60043070.6221420.00899681.0781770.7573638
 sp|P10619|PPGB_HUMANLysosomal protective protein0.85690010.48835630.69644240.04690680.93131510.868605
 sp|P52888|THOP1_HUMANThimet oligopeptidase0.96223950.73869750.8370720.04783161.314840.3072187
 sp|O96013|PAK4_HUMANSerine/threonine-protein kinase PAK 41.02173810.89206090.67658350.04100421.3337730.5003013
Common Proteins in 24 hr differentiation and GBCs
 sp|O43795|MYO1B_HUMANUnconventional myosin-Ib1.0242820.56355120.86921540.00268270.35336313.264E-06
 sp|Q9NZN4|EHD2_HUMANEH domain-containing protein 20.90124470.07390720.659330.00018310.23203045.896E-06
 sp|Q07954|LRP1_HUMANProlow-density lipoprotein receptor-related protein 10.87145870.00384840.67793635.012E-080.73061470.0002078
 sp|Q9H4M9|EHD1_HUMANEH domain-containing protein 10.94172560.25321930.83801130.0003650.53219785.697E-06
 sp|P80723|BASP1_HUMANBrain acid soluble protein 10.91160590.18196950.72027990.04107830.06769231.521E-07
 sp|P04844|RPN2_HUMANDolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 20.90170790.28786550.81921010.03992420.40753360.0022847
 sp|P30837|AL1B1_HUMANAldehyde dehydrogenase X, mitochondrial0.94170270.36825090.6707270.0017190.31645050.0001068
 sp|Q6WCQ1|MPRIP_HUMANMyosin phosphatase Rho-interacting protein0.93599790.28372410.8013440.00296360.53544060.0075895
 sp|P54727|RD23B_HUMANUV excision repair protein RAD23 homolog B0.88968540.14435520.79505440.01517750.61076980.0002073
 sp|P68032|ACTC_HUMANActin, alpha cardiac muscle 10.55448220.11495860.54089950.02602360.39122140.0114004
 sp|P98082|DAB2_HUMANDisabled homolog 20.96152060.61008790.77541980.01851350.38503270.0200069
 sp|P12111|CO6A3_HUMANCollagen alpha-3 (VI) chain1.3346690.00034280.80987020.00169860.38306870.0017061
 sp|Q969G5|PRDBP_HUMANProtein kinase C delta-binding protein0.94112120.53628160.86625210.0495860.29274896.347E-05
 sp|P62070|RRAS2_HUMANRas-related protein R-Ras20.81313210.10266540.76564060.041930.47471740.0066609
 sp|Q96KP4|CNDP2_HUMANCytosolic non-specific dipeptidase0.91732740.4109620.78315270.01472570.71928790.0329394
 sp|Q15758|AAAT_HUMANNeutral amino acid transporter B(0)1.0419950.55133520.84040370.04331460.63724340.0378501
 sp|Q15582|BGH3_HUMANTransforming growth factor-beta-induced protein ig-h30.96380070.71680770.43421450.00158910.1936040.0083622
 sp|Q9Y570|PPME1_HUMANProtein phosphatase methylesterase 10.80783680.07147560.77114140.00799410.64712390.0051838
 sp|Q9NRV9|HEBP1_HUMANHeme-binding protein 10.77281730.0539670.75150480.0246250.28967930.0215531
 sp|Q9UBG0|MRC2_HUMANC-type mannose receptor 20.78102440.11272530.67242970.01997270.32344290.01084
 sp|O14495|LPP3_HUMANLipid phosphate phosphohydrolase 30.74142590.11322760.7116510.01066890.19779740.0078443
 sp|O00461|GOLI4_HUMANGolgi integral membrane protein 40.92040730.4063720.77276060.03785640.70518540.0251325
 sp|Q16270|IBP7_HUMANInsulin-like growth factor-binding protein 70.3408610.06894170.31304950.03573960.17736820.0483662
Common Proteins in 12 hr differentiation and GBCs
 sp|P14618|KPYM_HUMANPyruvate kinase isozymes M1/M20.75919040.0015610.91498060.10269780.67290655.251E-05
 sp|P13639|EF2_HUMANElongation factor 20.79933082.653E-050.95365750.21112060.63092059.996E-09
 sp|P30101|PDIA3_HUMANProtein disulfide-isomerase A30.77317368.563E-051.0657630.23552340.55956114.566E-10
 sp|Q07065|CKAP4_HUMANCytoskeleton-associated protein 40.85857220.00565681.097070.03445480.67669711.092E-06
 sp|P09493|TPM1_HUMANTropomyosin alpha-1 chain0.38232380.00895290.72065820.18533210.19641610.0019547
 sp|P36578|RL4_HUMAN60S ribosomal protein L40.78183620.01210280.88419130.15889470.59384980.00011
 sp|Q15084|PDIA6_HUMANProtein disulfide-isomerase A60.82533820.03534441.1051190.15352150.51500380.000791
 sp|P67936|TPM4_HUMANTropomyosin alpha-4 chain0.63544120.00507570.96311360.8731890.41405340.0004444
 sp|Q9NR12|PDLI7_HUMANPDZ and LIM domain protein 70.85026560.00334570.97167070.72576220.21328734.529E-06
 sp|P62424|RL7A_HUMAN60S ribosomal protein L7a0.66310730.00907680.98614120.89995330.62029110.0028769
 sp|P26641|EF1G_HUMANElongation factor 1-gamma0.74628520.01863261.0470430.46702030.63361920.0009937
 sp|P18124|RL7_HUMAN60S ribosomal protein L70.79807750.01655881.044850.61653550.50232918.299E-05
 sp|Q02878|RL6_HUMAN60S ribosomal protein L60.76740080.00309890.89469290.06216240.53357393.795E-06
 sp|O15144|ARPC2_HUMANActin-related protein 2/3 complex subunit 20.78381750.00441240.94199520.53045310.53722796.401E-05
 sp|P60660|MYL6_HUMANMyosin light polypeptide 60.76169860.04950971.0683980.28866850.58326320.0147406
 sp|Q96HC4|PDLI5_HUMANPDZ and LIM domain protein 50.58921350.00081790.87705730.53148060.21181115.798E-06
 sp|P46781|RS9_HUMAN40S ribosomal protein S90.71640860.00569551.0132860.85411680.60844690.0008322
 sp|P62241|RS8_HUMAN40S ribosomal protein S80.7234990.0088181.12330.16910110.72303860.0046592
 sp|Q8TDX7|NEK7_HUMANSerine/threonine-protein kinase Nek70.80286380.00057250.88202050.02196380.24577375.175E-07
 sp|P63241|IF5A1_HUMANEukaryotic translation initiation factor 5A-10.8043850.03161321.1335150.28122480.58610240.0029435
 sp|P24844|MYL9_HUMANMyosin regulatory light polypeptide 90.7714090.03170430.8451170.09679340.20450510.0099072
 sp|P39019|RS19_HUMAN40S ribosomal protein S190.63524470.00162171.09884910.25988610.69857270.0125732
 sp|P62249|RS16_HUMAN40S ribosomal protein S160.8582360.00429111.2110660.00240160.71290091.012E-05
 sp|P21291|CSRP1_HUMANCysteine and glycine-rich protein 10.57830140.00769370.70483850.07513730.14013160.0004225
 sp|P62750|RL23A_HUMAN60S ribosomal protein L23a0.69309850.00086421.1890590.01703760.48741630.0005725
 sp|P27635|RL10_HUMAN60S ribosomal protein L100.76877110.00789340.99778110.97748360.78074550.0424448
 sp|P62244|RS15A_HUMAN40S ribosomal protein S15a0.62974690.03104081.24477510.24750550.39740150.006189
 sp|P40261|NNMT_HUMANNicotinamide N-methyltransferase0.49485440.01457190.61049290.0891450.40087260.0055721
 sp|O75396|SC22B_HUMANVesicle-trafficking protein SEC22b0.83834460.04774340.91347930.24899250.62306990.0051087
 sp|P63000|RAC1_HUMANRas-related C3 botulinum toxin substrate 10.71829430.04251750.96224060.68868510.46703970.0072975
 sp|P52565|GDIR1_HUMANRho GDP-dissociation inhibitor 10.63464890.02000630.91142260.24426280.55602550.0041023
 sp|Q02543|RL18A_HUMAN60S ribosomal protein L18a0.79893090.00545080.99875360.993140.59246630.001603
 sp|P31949|S10AB_HUMANProtein S100-A110.73160540.01059270.94860790.4543120.50937690.0051478
 sp|Q9NUQ6|SPS2L_HUMANSPATS2-like protein0.86038830.03775490.86795880.43576170.68445870.0203066
 sp|Q9UBY9|HSPB7_HUMANHeat shock protein beta-70.55918810.00391410.87184130.17648280.14348660.0124455
 sp|P62851|RS25_HUMAN40S ribosomal protein S250.75205750.02106421.2572620.02162260.6406930.0285225
 sp|P60866|RS20_HUMAN40S ribosomal protein S200.59224810.03722821.1359380.19522820.59719450.0331289
 sp|Q15121|PEA15_HUMANAstrocytic phosphoprotein PEA-150.74240160.03422240.84530320.23656560.55682120.01295
 sp|Q07020|RL18_HUMAN60S ribosomal protein L180.76942290.02847740.92284080.34251650.39172710.0355194
 sp|Q99584|S10AD_HUMANProtein S100-A130.67764130.01414110.9361090.6830510.40916210.0109403
 sp|Q96FQ6|S10AG_HUMANProtein S100-A160.75418280.01819020.78920960.14166640.44427750.0107498
 sp|Q9UK76|HN1_HUMANHematological and neurological expressed 1 protein0.69308780.00691850.83158140.05830530.63689850.0217168
 sp|P07951|TPM2_HUMANTropomyosin beta chain0.21819360.03015340.34760890.15043050.16994840.0294093
Common Proteins in 12, 24 and GBCs
 sp|P02452|CO1A1_HUMANCollagen alpha-1(I) chain0.17109519.168E-080.13827451.707E-130.08715991.366E-13
 sp|P08133|ANXA6_HUMANAnnexin A60.78434055.397E-050.83969468.225E-050.17533381.19E-12
 sp|P07355|ANXA2_HUMANAnnexin A20.77778950.01380440.85672270.00638940.64114939.041E-05
 sp|P08123|CO1A2_HUMANCollagen alpha-2 (I) chain0.22354074.04E-080.18556342.282E-120.14837533.537E-10
 sp|P04075|ALDOA_HUMANFructose-bisphosphate aldolase A0.76041780.00734060.86710050.01144240.71677170.0005067
 sp|P00558|PGK1_HUMANPhosphoglycerate kinase 10.58590950.00011530.65416148.688E-070.62266734.852E-07
 sp|P08729|K2C7_HUMANKeratin, type II cytoskeletal 70.36800293.277E-090.50835173.862E-100.06343084.792E-08
 sp|P04083|ANXA1_HUMANAnnexin A10.75728390.00020470.85032170.04707380.5500021.28E-07
 sp|P05783|K1C18_HUMANKeratin, type I cytoskeletal 180.41647451.808E-060.43013286.1E-070.10565354.488E-08
 sp|O75083|WDR1_HUMANWD repeat-containing protein 10.69175474.643E-060.73369820.00070940.38003381.092E-10
 sp|Q99715|COCA1_HUMANCollagen alpha-1 (XII) chain0.35459051.41E-130.28774284.501E-180.20265226.706E-15
 sp|Q96AC1|FERM2_HUMANFermitin family homolog 20.79502987.873E-060.85337280.00331120.21691331.367E-10
 sp|P13674|P4HA1_HUMANProlyl 4-hydroxylase subunit alpha-10.69467182.918E-060.61327921.034E-050.28746325.012E-08
 sp|O15460|P4HA2_HUMANProlyl 4-hydroxylase subunit alpha-20.66963453.711E-070.51435499.348E-080.26699693.101E-10
 sp|P42224|STAT1_HUMANSignal transducer and activator of transcription 1-alpha/beta0.84996980.00539610.78544320.00055950.43794525.75E-10
 sp|Q99536|VAT1_HUMANSynaptic vesicle membrane protein VAT-1 homolog0.83163660.01809530.81462530.01685690.20687850.0002163
 sp|Q9UHB6|LIMA1_HUMANLIM domain and actin-binding protein 10.74352012.34E-050.73507050.00054480.30195331.856E-08
 sp|Q14847|LASP1_HUMANLIM and SH3 domain protein 10.68226080.00400970.82059060.01252130.35137461.928E-06
 sp|Q9Y696|CLIC4_HUMANChloride intracellular channel protein 40.66354720.02986230.65655960.02945360.2592232.416E-06
 sp|P18669|PGAM1_HUMANPhosphoglycerate mutase 10.66003410.00057840.72908490.0002850.57374950.0001545
 sp|Q16222|UAP1_HUMANUDP-N-acetylhexosamine pyrophosphorylase0.67328540.00010790.78529860.00054870.37120675.819E-07
 sp|P02461|CO3A1_HUMANCollagen alpha-1 (III) chain0.22010810.00043930.18524120.00016740.12359140.0007796
 sp|O00469|PLOD2_HUMANProcollagen-lysine,2-oxoglutarate 5-dioxygenase 20.30109211.377E-050.34803981.46E-070.19495754.065E-06
 sp|P12109|CO6A1_HUMANCollagen alpha-1 (VI) chain0.46968238.107E-050.41696241.04E-060.72810330.001178
 sp|O00151|PDLI1_HUMANPDZ and LIM domain protein 10.85750810.00643860.8085830.00139040.71917940.0001499
 sp|Q9BUF5|TBB6_HUMANTubulin beta-6 chain0.53077260.00612570.60905870.00795620.2779190.0004736
 sp|O43399|TPD54_HUMANTumor protein D540.66862460.0054980.74177490.0113440.43927671.561E-05
 sp|P07858|CATB_HUMANCathepsin B0.70335790.0148440.68774660.00123510.29953720.0003164
 sp|Q02809|PLOD1_HUMANProcollagen-lysine,2-oxoglutarate 5-dioxygenase 10.84666750.00853380.84829340.0026770.36195844.314E-05
 sp|O15143|ARC1B_HUMANActin-related protein 2/3 complex subunit 1B0.6977380.02703380.845760.03510220.26516820.0004373
 sp|P12110|CO6A2_HUMANCollagen alpha-2 (VI) chain0.60120680.00881320.37897010.00070360.32067710.0017214
 sp|P21980|TGM2_HUMANProtein-glutamine gamma-glutamyltransferase 20.56930544.331E-050.6271920.00048740.19624460.0002049
 sp|P26373|RL13_HUMAN60S ribosomal protein L130.65725070.00102440.78346650.00952650.66305570.0040335
 sp|Q14192|FHL2_HUMANFour and a half LIM domains protein 20.78460960.00297670.81735970.00123080.27259180.0390995
 sp|Q93052|LPP_HUMANLipoma-preferred partner0.79901490.02257240.83379760.04065390.2927310.0001339
 sp|Q16647|PTGIS_HUMANProstacyclin synthase0.80802790.03197090.73242850.00193370.2638610.0002228
 sp|O15371|EIF3D_HUMANEukaryotic translation initiation factor 3 subunit D0.8647480.03838920.83463760.01674220.67142110.003605
 sp|Q13642|FHL1_HUMANFour and a half LIM domains protein 10.46097120.00011420.54274880.00019920.28292641.591E-06
 sp|P20908|CO5A1_HUMANCollagen alpha-1 (V) chain0.3793880.00683480.35447880.00032370.23535240.0026677
 sp|O60568|PLOD3_HUMANProcollagen-lysine,2-oxoglutarate 5-dioxygenase 30.76388090.00085310.80559490.00473010.5564660.0003241
 sp|P26022|PTX3_HUMANPentraxin-related protein PTX30.4165220.00403850.23222440.0005830.1864850.0139001
 sp|Q9H425|CA198_HUMANUncharacterized protein C1orf1980.6310390.01338040.62943320.00890140.2647520.0014479
 sp|P06756|ITAV_HUMANIntegrin alpha-V0.56139860.0181940.63850750.00165050.4827970.0014006
 sp|O15173|PGRC2_HUMANMembrane-associated progesterone receptor component 20.81957580.04471930.81435790.0415820.34420660.0120293
 sp|P05121|PAI1_HUMANPlasminogen activator inhibitor 10.37480780.0024110.28139750.00620540.17045240.0032371
 sp|P11047|LAMC1_HUMANLaminin subunit gamma-10.72046380.02639820.81159350.0477510.51659710.0042495
 sp|P41567|EIF1_HUMANEukaryotic translation initiation factor 10.59035460.00216220.59969680.00126220.81472020.0319759
 sp|P05787|K2C8_HUMANKeratin, type II cytoskeletal 80.70846520.03199260.67595410.01426140.37138690.0315686
 sp|P08729|K2C7_HUMANKeratin, type II cytoskeletal 70.36800293.277E-090.50835173.862E-100.06343084.792E-08
 sp|P05787|K2C8_HUMANKeratin, type II cytoskeletal 80.70846520.03199260.67595410.01426140.37138690.0315686

Table. 4.

Statistically significant neuronal and stress proteins expressed by induced stem cells at 12 and 24 hrs

Accession numberNameAccession numberName

Neurogenic related proteinsStress and shock related proteins
12 hour unique proteinsQ09666Neuroblast differentiation-associated proteinP09601Heme oxygenase
O94925GlutaminaseP48507Glutamate--cysteine ligase regulatory subunit
P12111Collagen alpha-3 (VI) chainP11413Glucose-6-phosphate 1-dehydrogenase
A1X283SH3 and PX domain-containing protein 2B
24 hour unique proteinsP23219Prostaglandin G/H synthase 1P23219Prostaglandin G/H synthase 1
P50402Emerin (wnt pathway)Q9Y547Heat shock protein beta-11
12 and 24 hour common proteinsGRP75Stress-70 protein
12 hours and GBC common proteinsP14136Glial fibrillary acidic protein
P15559NAD(P)H dehydrogenase (quinone) 1
Q2M2I8AP2-associated protein kinase 1
24 hours and GBC common proteinsQ06830Peroxiredoxin-1P04264Keratin, type II cytoskeletal 1
P09429High mobility group protein B1P04792Heat shock protein beta-1
P30048Thioredoxin-dependent peroxide reductaseP6160410 kDa heat shock protein, mitochondrial
P15121Aldose reductase

  1. Arvidson, K, Abdallah, BM, Applegate, LA, Baldini, N, Cenni, E, Gomez-Barrena, E, Granchi, D, Kassem, M, Konttinen, YT, Mustafa, K, Pioletti, DP, Sillat, T, and Finne-Wistrand, A (2011). Bone regeneration and stem cells. J Cell Mol Med. 15, 718-746.
  2. Moraleda, JM, Blanquer, M, Bleda, P, Iniesta, P, Ruiz, F, Bonilla, S, Cabanes, C, Tabares, L, and Martinez, S (2006). Adult stem cell therapy: dream or reality?. Transpl Immunol. 17, 74-77.
    Pubmed CrossRef
  3. Lu, P, Blesch, A, and Tuszynski, MH (2004). Induction of bone marrow stromal cells to neurons: differentiation, transdifferentiation, or artifact?. J Neurosci Res. 77, 174-191.
    Pubmed CrossRef
  4. Woodbury, D, Schwarz, EJ, Prockop, DJ, and Black, IB (2000). Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res. 61, 364-370.
    Pubmed CrossRef
  5. Zuk, PA, Zhu, M, Ashjian, P, De Ugarte, DA, Huang, JI, Mizuno, H, Alfonso, ZC, Fraser, JK, Benhaim, P, and Hedrick, MH (2002). Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 13, 4279-4295.
    Pubmed KoreaMed CrossRef
  6. Franco Lambert, AP, Fraga Zandonai, A, Bonatto, D, Cantarelli Machado, D, and Pêgas Henriques, JA (2009). Differentiation of human adipose-derived adult stem cells into neuronal tissue: does it work?. Differentiation. 77, 221-228.
    Pubmed CrossRef
  7. Barnabé, GF, Schwindt, TT, Calcagnotto, ME, Motta, FL, Martinez, G, de Oliveira, AC, Keim, LM, D’Almeida, V, Mendez-Otero, R, and Mello, LE (2009). Chemically-induced RAT mesenchymal stem cells adopt molecular properties of neuronal-like cells but do not have basic neuronal functional properties. PLoS One. 4, e5222.
    Pubmed KoreaMed CrossRef
  8. Unwin, RD, Smith, DL, Blinco, D, Wilson, CL, Miller, CJ, Evans, CA, Jaworska, E, Baldwin, SA, Barnes, K, Pierce, A, Spooncer, E, and Whetton, AD (2006). Quantitative proteomics reveals posttranslational control as a regulatory factor in primary hematopoietic stem cells. Blood. 107, 4687-4694.
    Pubmed CrossRef
  9. Takahashi, J, Palmer, TD, and Gage, FH (1999). Retinoic acid and neurotrophins collaborate to regulate neurogenesis in adult-derived neural stem cell cultures. J Neurobiol. 38, 65-81.
    Pubmed CrossRef
  10. White, K, Bruckner, JV, and Guess, WL (1973). Toxicological studies of 2-mercaptoethanol. J Pharm Sci. 62, 237-241.
    Pubmed CrossRef
  11. Bunnell, BA, Flaat, M, Gagliardi, C, Patel, B, and Ripoll, C (2008). Adipose-derived stem cells: isolation, expansion and differentiation. Methods. 45, 115-120.
    Pubmed KoreaMed CrossRef
  12. Jobbins, SE, Hill, CJ, D’Souza-Basseal, JM, Padula, MP, Herbert, BR, and Krockenberger, MB (2010). Immunoproteomic approach to elucidating the pathogenesis of cryptococcosis caused by Cryptococcus gattii. J Proteome Res. 9, 3832-3841.
    Pubmed CrossRef
  13. Taverner, T, Karpievitch, YV, Polpitiya, AD, Brown, JN, Dabney, AR, Anderson, GA, and Smith, RD (2012). DanteR: an extensible R-based tool for quantitative analysis of -omics data. Bioinformatics. 28, 2404-2406.
    Pubmed KoreaMed CrossRef
  14. Quesnel, C, Nardelli, L, Piednoir, P, Leçon, V, Marchal-Somme, J, Lasocki, S, Bouadma, L, Philip, I, Soler, P, Crestani, B, and Dehoux, M (2010). Alveolar fibroblasts in acute lung injury: biological behaviour and clinical relevance. Eur Respir J. 35, 1312-1321.
  15. Yamauchi, H, Miyamura, K, and Abo, M (2009). Proteomic assessment of important proteins for motor recovery in a rat model of photochemically-induced thrombosis. Journal of Applied Research. 9, 139-147.
  16. Marangos, PJ, and Schmechel, DE (1987). Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. Annu Rev Neurosci. 10, 269-295.
    Pubmed CrossRef
  17. Katsetos, CD, Legido, A, Perentes, E, and Mörk, SJ (2003). Class III beta-tubulin isotype: a key cytoskeletal protein at the crossroads of developmental neurobiology and tumor neuropathology. J Child Neurol. 18, 851-866.
  18. Kilroy, GE, Foster, SJ, Wu, X, Ruiz, J, Sherwood, S, Heifetz, A, Ludlow, JW, Stricker, DM, Potiny, S, Green, P, Halvorsen, YD, Cheatham, B, Storms, RW, and Gimble, JM (2007). Cytokine profile of human adipose-derived stem cells: expression of angiogenic, hematopoietic, and pro-inflammatory factors. J Cell Physiol. 212, 702-709.
    Pubmed CrossRef
  19. Safford, KM, Hicok, KC, Safford, SD, Halvorsen, YD, Wilkison, WO, Gimble, JM, and Rice, HE (2002). Neurogenic differentiation of murine and human adipose-derived stromal cells. Biochem Biophys Res Commun. 294, 371-379.
    Pubmed CrossRef
  20. Kikuchi, G, Yoshida, T, and Noguchi, M (2005). Heme oxygenase and heme degradation. Biochem Biophys Res Commun. 338, 558-567.
    Pubmed CrossRef
  21. Vile, GF, Basu-Modak, S, Waltner, C, and Tyrrell, RM (1994). Heme oxygenase 1 mediates an adaptive response to oxidative stress in human skin fibroblasts. Proc Natl Acad Sci U S A. 91, 2607-2610.
    Pubmed KoreaMed CrossRef
  22. Motterlini, R, Foresti, R, Bassi, R, and Green, CJ (2000). Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radic Biol Med. 28, 1303-1312.
    Pubmed CrossRef
  23. Mehindate, K, Sahlas, DJ, Frankel, D, Mawal, Y, Liberman, A, Corcos, J, Dion, S, and Schipper, HM (2001). Proinflammatory cytokines promote glial heme oxygenase-1 expression and mitochondrial iron deposition: implications for multiple sclerosis. J Neurochem. 77, 1386-1395.
    Pubmed CrossRef
  24. Chen, K, Gunter, K, and Maines, MD (2000). Neurons overexpressing heme oxygenase-1 resist oxidative stress-mediated cell death. J Neurochem. 75, 304-313.
    Pubmed CrossRef
  25. Radtke, S, Wüller, S, Yang, XP, Lippok, BE, Mütze, B, Mais, C, de Leur, HS, Bode, JG, Gaestel, M, Heinrich, PC, Behrmann, I, Schaper, F, and Hermanns, HM (2010). Cross-regulation of cytokine signalling: pro-inflammatory cytokines restrict IL-6 signalling through receptor internalisation and degradation. J Cell Sci. 123, 947-959.
    Pubmed CrossRef
  26. Krzywanski, DM, Dickinson, DA, Iles, KE, Wigley, AF, Franklin, CC, Liu, RM, Kavanagh, TJ, and Forman, HJ (2004). Variable regulation of glutamate cysteine ligase subunit proteins affects glutathione biosynthesis in response to oxidative stress. Arch Biochem Biophys. 423, 116-125.
    Pubmed CrossRef
  27. Dasgupta, A, Das, S, and Sarkar, PK (2007). Thyroid hormone promotes glutathione synthesis in astrocytes by up regulation of glutamate cysteine ligase through differential stimulation of its catalytic and modulator subunit mRNAs. Free Radic Biol Med. 42, 617-626.
    Pubmed CrossRef
  28. Lavoie, S, Chen, Y, Dalton, TP, Gysin, R, Cuénod, M, Steullet, P, and Do, KQ (2009). Curcumin, quercetin, and tBHQ modulate glutathione levels in astrocytes and neurons: importance of the glutamate cysteine ligase modifier subunit. J Neurochem. 108, 1410-1422.
    Pubmed CrossRef
  29. Efferth, T, Schwarzl, SM, Smith, J, and Osieka, R (2006). Role of glucose-6-phosphate dehydrogenase for oxidative stress and apoptosis. Cell Death Differ. 13, 527-528.
  30. Mejías, R, Villadiego, J, Pintado, CO, Vime, PJ, Gao, L, Toledo-Aral, JJ, Echevarría, M, and López-Barneo, J (2006). Neuroprotection by transgenic expression of glucose-6-phosphate dehydrogenase in dopaminergic nigrostriatal neurons of mice. J Neurosci. 26, 4500-4508.
    Pubmed CrossRef
  31. O’Banion, MK, Miller, JC, Chang, JW, Kaplan, MD, and Coleman, PD (1996). Interleukin-1 beta induces prostaglandin G/H synthase-2 (cyclooxygenase-2) in primary murine astrocyte cultures. J Neurochem. 66, 2532-2540.
  32. Hollebeeck, S, Raas, T, Piront, N, Schneider, YJ, Toussaint, O, Larondelle, Y, and During, A (2011). Dimethyl sulfoxide (DMSO) attenuates the inflammatory response in the in vitro intestinal Caco-2 cell model. Toxicol Lett. 206, 268-275.
    Pubmed CrossRef
  33. Asmis, L, Tanner, FC, Sudano, I, Lüscher, TF, and Camici, GG (2010). DMSO inhibits human platelet activation through cyclooxygenase-1 inhibition. A novel agent for drug eluting stents?. Biochem Biophys Res Commun. 391, 1629-1633.
  34. Benagiano, M, D’Elios, MM, Amedei, A, Azzurri, A, van der Zee, R, Ciervo, A, Rombolà, G, Romagnani, S, Cassone, A, and Del Prete, G (2005). Human 60-kDa heat shock protein is a target auto-antigen of T cells derived from atherosclerotic plaques. J Immunol. 174, 6509-6517.
    Pubmed CrossRef
  35. Morano, KA (2007). New tricks for an old dog: the evolving world of Hsp70. Ann N Y Acad Sci. 1113, 1-14.
    Pubmed CrossRef
  36. Paul Chapple, J, Smerdon, GR, and Hawkins, AJS (1997). Stress-70 protein induction in Mytilus edulis: Tissue-specific responses to elevated temperature reflect relative vulnerability and physiological function. Journal of Experimental Marine Biology and Ecology. 217, 225-235.
  37. Ricaniadis, N, Kataki, A, Agnantis, N, Androulakis, G, and Karakousis, CP (2001). Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma. Eur J Surg Oncol. 27, 88-93.
    Pubmed CrossRef
  38. Lüders, J, Demand, J, and Höhfeld, J (2000). The ubiquitin-related BAG-1 provides a link between the molecular chaperones Hsc70/Hsp70 and the proteasome. J Biol Chem. 275, 4613-4617.
    Pubmed CrossRef
  39. Jakob, U, Gaestel, M, Engel, K, and Buchner, J (1993). Small heat shock proteins are molecular chaperones. J Biol Chem. 268, 1517-1520.
  40. Kiang, JG, and Tsokos, GC (1998). Heat shock protein 70 kDa: molecular biology, biochemistry, and physiology. Pharmacol Ther. 80, 183-201.
    Pubmed CrossRef

November 2017, 10 (2)